Report of the Standardized Outcomes in Nephrology-transplant Consensus Workshop on Establishing a Core Outcome Measure for Infection in Kidney Transplant Recipients.

Competing Interests: S.C. is supported by the Australian National Health and Medical Research Council Emerging Leadership Scholarship and the Royal Australasian College of Physicians Research Establishment Fellowship. C.H. is the recipient of research grants paid to her institution from Baxter Health and Fresenius Medical Care and from Otsuka, Janssen, and GlaxoSmithKline for trial steering committee activities, paid to her institution. D.J. has received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Health and Fresenius Medical Care. He has received consultancy fees from AstraZeneca, Bayer, and AWAK; speaker’s honoraria from Ono and BI and Lilly; and travel sponsorships from Amgen. He is a current recipient of an Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grant. A.J. is supported by the NHMRC Research Fellowship. A.V. receives grant support from the Royal Australasian College of Physicians (Jacquot Research Establishment Award) and the Princess Alexandra Research Foundation. D.C.B. receives institutional research grant funding from CareDx and is a consultant for CareDx, Medeor, Sanofi, and Vera Therapeutics and is supported by National Institute of Diabetes and Digestive and Kidney Diseases U01 DK116042, U01AI063594, and R44DK123978. E.B. receives research support from Merck, Takeda and Hologix, and DSMB for Amplyx and is an unpaid consultant for Merck and Takeda. Y.C. has received research grants and speaker’s honoraria from Baxter Health and Fresenius Medical Care and is a current recipient of an Australian NHMRC Emerging Leadership Investigator Grant and Queensland Health Advancing Care Fellowship (mid-career). The other authors declare no conflicts of interest.